Bavarian Nordic Announces Major Contract for Smallpox Vaccine

U.S. Government Places Substantial Order to Replenish Stockpiles

Order to Support Future Manufacturing and Supply of Freeze-Dried Vaccine

Bavarian Nordic A/S, a leading biotechnology company specializing in vaccines and immunotherapies, has announced a significant contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the supply of its smallpox vaccine, Jynneos.

The contract, valued at an undisclosed amount, will help replenish the U.S. government's stockpile of bulk vaccine, ensuring a sufficient supply for future manufacturing and distribution of the freeze-dried vaccine. Jynneos is a non-replicating smallpox vaccine that has been approved for use in both adults and children and has demonstrated high efficacy and safety.

Bavarian Nordic's CEO, Paul Chaplin, stated that the contract would not impact the company's overall financial guidance for the year. However, he emphasized its importance in supporting future production and supply of the vaccine, which remains a critical component of the U.S. government's public health preparedness strategy.